Background. Transcatheter device occlusion of atrial septal defects is an attractive approach, but its efficacy and place in patient management remain to be determined.
T he technique of transcatheter occlusion of atrial septal defects with a variety of devices has evolved since the initial concept was developed more than 15 years ago,l-3 with recent reports of successful catheter closure with a Dacron clamshell double-umbrella device (Billerica, Mass) that has an apparent low rate of complications (eg, residual leaks, device embolization, venous thrombosis, atrioventricular valve problems, bacterial endocarditis).2,3 Because this approach obviates the need for open-heart surgery and blood exposure and reduces the period of hospitalization, recovery, and costs, it becomes a very attractive approach to health care delivery. The efficacy of catheter occlusion can be determined only, however, after careful follow-up to establish its proper place in patient management.
We reviewed the echocardiographic follow-up of patients who underwent transcatheter atrial septal defect closure, assessed the success rates, and compared clo-sure rates with those of a cohort of patients who underwent surgical closure. The study also attempts to determine if a relation exists between the presence of residual shunting and (1) defect location, (2) dimension and location of residual shunt(s) after occlusion, and (3) device size relative to the atrial septal defect dimension. Finally, comparison of transesophageal echocardiographic findings in the immediate postocclusion period with those detected with transthoracic echocardiography during medium-term follow-up were reviewed. 
Methods

Control Population
After either suture or patch atrial septal defect closure, 48 patients were reviewed as part of their routine follow-up for repair of associated congenital heart anomalies.
Study Protocol
Patients were screened with a transthoracic echocardiographic study, and those with a central secundum atrial septal defect measuring 20 mm or less were further evaluated with transesophageal echocardiography (Aloka SSD-870 ultrasound system, with a 5-MHz biplane transesophageal probe) while under general anesthesia, just before cardiac catheterization. The transesophageal echocardiographic study defined the position and dimension of the atrial defect, identified associated lesions, and excluded others that would preclude the patient from catheter closure (ie, partial anomalous pulmonary venous drainage, sinus venosus defect, multiple atrial septal defects, and insufficient tissue rim between the edges of the defect and important cardiac structures). Not infrequently, the transesophageal study demonstrated a defect 3 to 5 mm smaller than that detected by transthoracic echocardiography due to improved near-field resolution. All patients underwent catheter sizing with a 22-mm balloon (Meditech, Mansefield, Pa) to establish a stretched diameter, which was then used to select the appropriate occluder device. Device diameters were chosen to be at least 1.8-fold the stretched defect size. The defect size as assessed by transesophageal echocardiography ranged from 4 to 16 mm (mean, 10 mm) in both longitudinal and transverse planes. The mean diameter by balloon sizing was 13 mm (range, 4 to 20 mm). In 48 of 49 patients, the ratio of the device size to the atrial septal defect dimension when stretched by balloon catheter (D/S ratio) could be measured (Table) valve and the atrial septum, and apical four-chamber views were particularly useful. Precise location and measurement of any residual shunt(s) were noted, as were device position, right ventricular dimension, and septal motion. Evolution of the heart size along with the auscultatory findings also were assessed at follow-up.
Definition of Residual Shunts
Residual shunting was classified to be through the device if a leak, as identified by two-dimensional color flow Doppler and/or pulsed Doppler, was traversing the material or passing between the two shells of the device, or around the device or if residual flow was demonstrated around the device edges (Fig 1) ence was found between these two groups with regard to the initial size of the residual shunt as assessed by transesophageal echocardiography and the probability of disappearance at follow-up.
In the same group of 26 patients with residual shunting at follow-up, the initial transesophageal examination revealed shunting through the device in 12 of 33 and around the device in 21 of 33 shunts (7 of 26 patients had 2 residual shunts at transesophageal evaluation). Of those with no residual shunting at follow-up, the initial transesophageal study demonstrated 11 shunts through and 7 around the device. Statistically, there was no significant difference between the two groups regarding the probability of complete occlusion at follow-up. Similarly, there was no difference between the two groups with regard to shunt location in the patients in whom the leak was around the device.
No difference existed between the D/S ratio of pa- During follow-up, variability in serial transthoracic echocardiographic findings relating to the presence and the location of residual shunts was observed in 14 of 49 patients (29%). In 12 patients, the ability to image a residual shunt varied, whereas in 2, there was difficulty in differentiating shunting through or around the device.
Right Ventricular Dimension and Septal Motion
For the duration of follow-up, no significant decrease in right ventricular end-diastolic dimension was observed after device occlusion (1.93±0.52 versus 1.89±0.59 cm). In 7 patients, the septal motion was still abnormal at the termination of this follow-up. No correlation was found between right ventricular dimension and septal motion at follow-up and the presence or size of residual shunting.
Clinical Findings
Of the 43 patients without an associated cardiac abnormality, 37% had a residual grade 1 or 2/6 systolic murmur with none having a tricuspid flow murmur. Four of the remaining patients had a residual systolic murmur secondary to their underlying associated abnormality. The second heart sound was normal at the most recent examination in those with an isolated secundum atrial septal defect.
Heart size and pulmonary vascularity on chest radiography returned to normal at follow-up in all except three patients. One did not have any residual left-toright shunting but is followed for a dilated cardiomyopathy secondary to endocardial fibroelastosis; one has moderate tricuspid regurgitation; and the third patient had a persistently enlarged heart despite no residual shunting at the most recent echocardiographic evaluation.
No correlation was found between clinical and radiological findings and the presence or absence of residual shunting. Discussion The principal aim of this study was to evaluate the rate of successful atrial septal defect occlusion using a percutaneous catheter-placed device. In our experience, after a mean follow-up of 10 months, 47% of patients were free of residual shunting. In another study evaluocclusion, a success rate of 63% (12 of the subgroup of 19 patients followed by transthoracic echocardiography) was noted.2 The number of patients studied as well as patient selection may have contributed to a discrepancy between results. In that study,2 3 patients had a patent foramen ovale closed, and 15 of 40 patients (37% of the group) had closure of a Fontan patch leak or superior vena cava-to-atrial shunt. Our population, however, consists mainly of patients with an isolated secundum atrial septal defect, in whom the defect dimension tends to be larger than in those with a residual baffle leak, patent foramen ovale, or fenestrated Fontan.
Actuarial analysis of our results correlating the rate of residual shunting after device occlusion to the follow-up period demonstrates an ongoing spontaneous resolution of residual shunting long after device insertion. This is similar to the reported continual resolution of residual shunting after ductal occlusion with the Rashkind device. 6, 7 Neither the initial atrial septal defect dimension, defect location before implantation, nor location of a residual shunt immediately after closure appears to influence the success rate of complete occlusion. Our data also support the notion that residual shunts through the device disappear at a similar rate to those occurring around the device. In addition, results show that residual anterior shunts are just as likely to close with time compared with their superior counterparts. Similarly, shunts of medium size are as likely as trace or small shunts to disappear at follow-up. Of interest, we observed no difference between the D/S ratio in the group with residual shunting at follow-up compared with those in whom successful closure was achieved, which is different than data reported by Rome and colleagues.2 In the majority of our patients (69%), the echocardiographic right ventricular end-diastolic dimension did not return to normal; however, this is to be expected considering that the mean follow-up was only 10 months. This is supported by previous literature reporting that 6 to 12 months may be necessary for normalization of right ventricular dimension. suggests an ongoing spontaneous resolution of residual atrial septal defect shunting after device insertion. In our series, residual shunting rarely is observed after surgical closure of an atrial septal defect. The probability of eventual disappearance of residual shunting either through or around the device is not influenced by the initial location or dimension, by the preocclusion location of the atrial septal defect, or by the D/S ratio. Finally, reliability of transthoracic echocardiography in the follow-up of patients after atrial septal defect device occlusion remains to be determined.
